Bleomycin, also known as bleomycin sulfate or BLM, belongs to the class of organic compounds known as hybrid glycopeptides. Hybrid glycopeptides are compounds containing a carbohydrate component linked to a hybrid peptide component. Thus, bleomycin is considered to be a non-ribosomal peptide/polyketide hybrid lipid molecule. Bleomycin is a drug which is used for palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. Bleomycin is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Bleomycin is formally rated as a possible carcinogen (by IARC 2B) and is also a potentially toxic compound. Bleomycin A2 is used as the representative structure for Bleomycin. Bleomycin may cause irritation to eyes, skin and respiratory tract.